Related Experiment Video
Updated: Sep 17, 2025
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Innately Fluorescent Tetravalent Cytotoxic Conjugate TetraFHER2-vcMMAE Engages Aggregation-Dependent Endocytosis of
Natalia Porębska1, Aleksandra Chorążewska1, Krzysztof Ciura1
1Department of Medical Biotechnology, Faculty of Biotechnology, University of Wroclaw, F. Joliot-Curie 14a, 50-383 Wroclaw, Poland.
Abstract:
Breast cancer is the most common malignancy in women, with approximately 20-30% of all diagnosed cases characterized by HER2 overexpression. Several HER2-targeted cytotoxic conjugates have been developed, but their efficacy is limited. One of the main obstacles restraining the effectiveness of HER2-specific cytotoxic conjugates is their low internalization, as HER2 is immobile mainly on the cell surface. Therefore, there is a need to develop novel HER2-selective cytotoxic conjugates that will overcome HER2 immovability and, by this, ensure efficient drug delivery into HER2-overexpressing cancer cells. Here, we present a novel system for generating high affinity, self-assembling, inherently fluorescent, and multivalent HER2 ligands. The developed HER2-specific ligands largely overcome the innate stability of HER2 in the plasma membrane by triggering clathrin-independent aggregation-dependent endocytosis of the receptor. To exploit the pro-endocytic potential of developed proteins, we constructed the tetravalent fluorescent cytotoxic conjugate TetraFHER2-vcMMAE and demonstrated its high potency and selectivity against HER2+ breast cancer cells.
Insights
Researchers developed a novel HER2-targeted therapy that enhances drug delivery into HER2-positive breast cancer cells by overcoming receptor immobility. This new approach improves the efficacy of cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer is a leading malignancy in women, with HER2 overexpression present in 20-30% of cases.
- Current HER2-targeted therapies face limitations due to low drug internalization, stemming from HER2 receptor immobility on the cell surface.
Purpose of the Study:
- To develop novel HER2-selective cytotoxic conjugates that overcome HER2 immobility for efficient drug delivery.
- To create a system for generating high-affinity, self-assembling, fluorescent, and multivalent HER2 ligands.
Main Methods:
- Engineered novel HER2-specific ligands designed to induce clathrin-independent, aggregation-dependent endocytosis.
- Constructed a tetravalent fluorescent cytotoxic conjugate, TetraFHER2-vcMMAE, utilizing the developed ligands.
Main Results:
- The developed HER2 ligands effectively triggered receptor endocytosis, overcoming HER2 plasma membrane stability.
- The TetraFHER2-vcMMAE conjugate demonstrated high potency and selectivity against HER2-positive breast cancer cells.
Conclusions:
- Novel HER2 ligands can overcome receptor immobility and enhance endocytosis.
- The developed TetraFHER2-vcMMAE conjugate represents a promising therapeutic strategy for HER2-positive breast cancer.
